Literature DB >> 16966018

Dermatomyositis.

Jeffrey P Callen1, Robert L Wortmann.   

Abstract

Dermatomyositis is one of the idiopathic inflammatory myopathies. It is characterized clinically by progressive symmetrical proximal muscle weakness and a characteristic rash. There are patients with rash who have little or no muscle disease. Although the process primarily attacks the skin and the muscles, it is a systemic disease with frequent manifestations in the gastrointestinal tract and pulmonary system. Dermatomyositis has been linked to internal malignancy in somewhere between 15% and 25%. Therapy for the muscle disease includes systemic corticosteroids with or without an immunosuppressive agent. Therapy of the skin disease begins with photoprotection and topical corticosteroids, but also includes the use of antimalarial agents and immunomodulatory therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16966018     DOI: 10.1016/j.clindermatol.2006.07.001

Source DB:  PubMed          Journal:  Clin Dermatol        ISSN: 0738-081X            Impact factor:   3.541


  39 in total

Review 1.  [Current treatments of dermatomyositis and polymyositis].

Authors:  J Richter; C Iking-Konert
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

2.  UV radiation regulates Mi-2 through protein translation and stability.

Authors:  Craig J Burd; H Karimi Kinyamu; Frederick W Miller; Trevor K Archer
Journal:  J Biol Chem       Date:  2008-10-15       Impact factor: 5.157

3.  When myopathy strikes in a cancer patient.

Authors:  Srivalli Gopaluni; Lilian M Thomas; Chirag Shah
Journal:  Gastrointest Cancer Res       Date:  2009-09

4.  Dermatomyositis and small cell carcinoma of the bladder.

Authors:  Lior Sagi; Boaz Amichai; Aviv Barzilai; Dorit Shpiro; Sharon Baum; Alexei Neimushin; Merav Lidar; Henri Trau
Journal:  Can Fam Physician       Date:  2009-10       Impact factor: 3.275

5.  Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.

Authors:  Renato Goreshi; Joyce Okawa; Matt Rose; Rui Feng; Lela A Lee; Christopher B Hansen; Carolyn A Bangert; M Kari Connolly; Mark D Davis; Jeff P Callen; Nicole M Fett; Steven S Fakharzadeh; Jennie T Clarke; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

Review 6.  [Paraneoplastic autoimmune dermatoses].

Authors:  D Didona; M Hertl
Journal:  Hautarzt       Date:  2021-03-01       Impact factor: 0.751

Review 7.  Recent Advances in Pharmacological Treatments of Adult Dermatomyositis.

Authors:  Kristen L Chen; Majid Zeidi; Victoria P Werth
Journal:  Curr Rheumatol Rep       Date:  2019-08-31       Impact factor: 4.592

Review 8.  Polymyositis/dermatomyositis associated with acute myelocytic leukemia.

Authors:  Jia-Kun Shen; Yong-Min Ding; Wen-Jing Zhou; Jie Jin
Journal:  Rheumatol Int       Date:  2008-06-19       Impact factor: 2.631

9.  Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

Authors:  Paige W Wolstencroft; Lorinda Chung; Shufeng Li; Livia Casciola-Rosen; David F Fiorentino
Journal:  JAMA Dermatol       Date:  2018-01-01       Impact factor: 10.282

10.  Clinical characteristics and outcomes of juvenile and adult dermatomyositis.

Authors:  Sang-Jun Na; Seung Min Kim; Il Nam Sunwoo; Young-Chul Choi
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.